These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2979054)

  • 1. Experimental application of target-specific immunoconjugates containing daunomycin as the cytocidal component.
    Diener E; Xie SS; Yu LZ; Longenecker BM; Sinha AA
    Targeted Diagn Ther; 1988; 1():1-23. PubMed ID: 2979054
    [No Abstract]   [Full Text] [Related]  

  • 2. Application of target-specific drug immunoconjugates to experimental bone marrow replacement therapy in mice.
    Ding L; Yu LZ; Xie SS; Gong D; Vergidis R; Diener E
    Cancer Res; 1990 Mar; 50(5):1538-43. PubMed ID: 2302715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.
    Stastny JJ; Das Gupta TK
    Cancer Res; 1993 Dec; 53(23):5740-4. PubMed ID: 8242630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the cytotoxic activity of the immunotoxins with different internalization rate.
    Tonevitsky AG; Agapov II; Mechetner EB; Ershova GV; Toptygin AYu ; Sarma T; Shamshiev AT; Pfueller U
    Biochem Mol Biol Int; 1993 Dec; 31(6):1059-69. PubMed ID: 8193589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of anthracycline-antibody complexes for specific antitumor activity.
    Pietersz GA; Smyth MJ; Farquhar I; McKenzie C
    Targeted Diagn Ther; 1988; 1():25-53. PubMed ID: 2979059
    [No Abstract]   [Full Text] [Related]  

  • 6. Specific immunosuppression by immunotoxins containing daunomycin.
    Diener E; Diner UE; Sinha A; Xie S; Vergidis R
    Science; 1986 Jan; 231(4734):148-50. PubMed ID: 3484557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coupling daunorubicin to monoclonal antialphafoetoprotein with a new activated derivative.
    Thibeault D; Pagé M
    Int J Immunopharmacol; 1990; 12(5):503-7. PubMed ID: 1698734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug.
    Dillman RO; Johnson DE; Shawler DL; Koziol JA
    Cancer Res; 1988 Nov; 48(21):6097-102. PubMed ID: 3262420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice.
    Funakoshi S; Taub DD; Anver MR; Raziuddin A; Asai O; Reddy V; Rager H; Fanslow WC; Longo DL; Murphy WJ
    J Clin Invest; 1997 Feb; 99(3):484-91. PubMed ID: 9022082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
    Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
    Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daunomycin pharmacological activity at the cellular level.
    Di Marco A
    Pathol Biol; 1967 Oct; 15(19):897-902. PubMed ID: 4297686
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment.
    Neville DM
    Crit Rev Ther Drug Carrier Syst; 1986; 2(4):329-52. PubMed ID: 3549005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis.
    Zhang Y; Lu L; Furlonger C; Wu GE; Paige CJ
    Nat Immunol; 2000 Nov; 1(5):392-7. PubMed ID: 11062498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of action of chemotherapy in vivo on human acute leukemia. I. Daunomycin.
    Stryckmans PA; Manaster J; Lachapelle F; Socquet M
    J Clin Invest; 1973 Jan; 52(1):126-33. PubMed ID: 4509140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer.
    Smyth MJ; Pietersz GA; Farquhar I; McKenzie C
    Targeted Diagn Ther; 1988; 1():123-56. PubMed ID: 2979055
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo administration of insulin-like growth factor-I stimulates primary B lymphopoiesis and enhances lymphocyte recovery after bone marrow transplantation.
    Jardieu P; Clark R; Mortensen D; Dorshkind K
    J Immunol; 1994 May; 152(9):4320-7. PubMed ID: 8157955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of acute myeloid leukemia in adults with a combination of daunomycin and cytosine-arabinoside].
    Brincker H
    Ugeskr Laeger; 1972 Oct; 134(42):2195-200. PubMed ID: 4563112
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of cytosine arabinoside, daunomycin, mithramycin, azacytidine, adriamycin, and camptothecin on mammalian cell cycle traverse.
    Tobey RA
    Cancer Res; 1972 Dec; 32(12):2720-5. PubMed ID: 4118765
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibodies and immunoconjugates for cancer treatment.
    Baldwin RW; Byers VS
    Cancer Chemother Biol Response Modif; 1987; 9():409-31. PubMed ID: 3079412
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.